Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Sexually Transmitted Infections · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 25%Very low 3 · 75%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Oral drug treatment vs topical treatments

Primary outcome 1: Number of clinical recurrences per participant per year · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis

1 finding from 1 review

Treatment for recurrent vulvovaginal candidiasis (thrush) 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral drug treatment vs topical treatments

Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis

It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 6 months compared with topical drug treatment (very low certainty).

1 finding from 1 review

Treatment for recurrent vulvovaginal candidiasis (thrush) 2022 · Cochrane Headline outcomes only
RR 1.66 [0.83, 3.31]
3 studies · 206 participants
Very low

Oral drug treatment vs topical treatments

Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis

It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 12 months compared with topical drug treatment (very low certainty).

1 finding from 1 review

Treatment for recurrent vulvovaginal candidiasis (thrush) 2022 · Cochrane Headline outcomes only
RR 0.95 [0.71, 1.27]
3 studies · 206 participants
Very low

Oral drug treatment vs topical treatments

Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis

1 finding from 1 review

Treatment for recurrent vulvovaginal candidiasis (thrush) 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3 participants
Very low